Cargando…

Potential anti-cancer effect of N-hydroxy-7-(2-naphthylthio) heptanomide (HNHA), a novel histone deacetylase inhibitor, for the treatment of thyroid cancer

BACKGROUND: Thyroid cancer has been indicated to have a higher global proportion of DNA methylation and a decreased level of histone acetylation. Previous studies showed that histone gene reviser and epigenetic changes role significant parts in papillary and anaplastic thyroid cancer tumorigenesis....

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Seok-Mo, Park, Ki-Cheong, Jeon, Jeong-Yong, Kim, Bup-Woo, Kim, Hyeung-Kyoo, Chang, Ho-Jin, Choi, Seung-Hoon, Park, Cheong-Soo, Chang, Hang-Seok
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4690331/ https://www.ncbi.nlm.nih.gov/pubmed/26698299 http://dx.doi.org/10.1186/s12885-015-1982-6

Ejemplares similares

Synergistic Activity of N-hydroxy-7-(2-naphthylthio) Heptanomide and Sorafenib Against Cancer Stem Cells, Anaplastic Thyroid Cancer
por: Park, Ki Cheong, et al.
Publicado: (2017)

Corrigendum to “Synergistic Activity of N-Hydroxy-7-(2-Naphthylthio) Heptanomide and Sorafenib against Cancer Stem Cells, Anaplastic Thyroid Cancer” [Neoplasia 19 (2017) 145-153]
por: Park, Ki Cheong, et al.
Publicado: (2017)

Synergistic Anticancer Activity of N-Hydroxy-7-(2-Naphthylthio) Heptanomide, Sorafenib, and Radiation Therapy in Patient-Derived Anaplastic Thyroid Cancer Models
por: Yun, Hyeok Jun, et al.
Publicado: (2021)

Anti-cancer Effects of HNHA and Lenvatinib by the Suppression of EMT-Mediated Drug Resistance in Cancer Stem Cells()()
por: Lee, Yong Sang, et al.
Publicado: (2018)

The novel histone deacetylase inhibitor, N-hydroxy-7-(2-naphthylthio) hepatonomide, exhibits potent antitumor activity due to cytochrome-c-release-mediated apoptosis in renal cell carcinoma cells
por: Park, Ki Cheong, et al.
Publicado: (2015)

Diagnostic Thyroidectomy May Be Preferable in Patients With Suspicious Ultrasonography Features After Cytopathology Diagnosis of AUS/FLUS in the Bethesda System
por: Lee, Yong Sang, et al.
Publicado: (2015)

SoLAT (Sorafenib Lenvatinib alternating treatment): a new treatment protocol with alternating Sorafenib and Lenvatinib for refractory thyroid Cancer
por: Kim, Soo Young, et al.
Publicado: (2018)

Safety of Tyrosine Kinase Inhibitors in Patients With Differentiated Thyroid Cancer: Real-World Use of Lenvatinib and Sorafenib in Korea
por: Kim, Soo Young, et al.
Publicado: (2019)

The Clinical Significance of the Right Para-Oesophageal Lymph Nodes in Papillary Thyroid Cancer
por: Chang, Hojin, et al.
Publicado: (2015)

Difficult evaluation of thyroid cancer due to cervical paraffin injection
por: Lee, Yong Sang, et al.
Publicado: (2011)

Parathyroid score can predict the duration of required calcium supplementation after total thyroidectomy
por: Kim, Bup-Woo, et al.
Publicado: (2017)

Survival With Lenvatinib for the Treatment of Progressive Anaplastic Thyroid Cancer: A Single-Center, Retrospective Analysis
por: Kim, Soo Young, et al.
Publicado: (2020)

Overcoming the Limitations of Fine Needle Aspiration Biopsy: Detection of Lateral Neck Node Metastasis in Papillary Thyroid Carcinoma
por: Jun, Hak Hoon, et al.
Publicado: (2015)

Impact of Age-Related Genetic Differences on the Therapeutic Outcome of Papillary Thyroid Cancer
por: Kim, Seok-Mo, et al.
Publicado: (2020)

Solitary lateral neck node metastasis in papillary thyroid carcinoma
por: Kim, Seok-Mo, et al.
Publicado: (2014)

Ultrasonographic features and clinicopathologic characteristics of macrofollicular variant papillary thyroid carcinoma
por: Lee, Yong Sang, et al.
Publicado: (2018)

On-site ultrasound-guided localization for impalpable nodal recurrences in papillary thyroid carcinoma patients
por: Kim, Kuk-Jin, et al.
Publicado: (2013)

Thyroid Hormone Supplementation Therapy for Differentiated Thyroid Cancer After Lobectomy: 5 Years of Follow-Up
por: Kim, Soo Young, et al.
Publicado: (2020)

Long-term survival of patients with anaplastic thyroid cancer after multimodal treatment
por: Lee, Haejun, et al.
Publicado: (2020)

Histone Acetylation Level and Histone Acetyltransferase/Deacetylase Activity in Ejaculated Sperm from Normozoospermic Men
por: Kim, Jee Hyun, et al.
Publicado: (2014)

Histone Deacetylases and Their Regulatory MicroRNAs in Hepatocarcinogenesis
por: Kim, Hyung Seok, et al.
Publicado: (2015)

Tumor Margin Histology Predicts Tumor Aggressiveness in Papillary Thyroid Carcinoma: A Study of 514 Consecutive Patients
por: Kim, Kuk-Jin, et al.
Publicado: (2011)

A new histone deacetylase inhibitor improves liverfibrosis in BDL rats through suppression of hepatic stellate cells
por: Park, Ki Cheong, et al.
Publicado: (2014)

Prognosis of Anaplastic Thyroid Cancer with Distant Metastasis
por: Lee, Jin-Seok, et al.
Publicado: (2022)

Cervical bronchogenic cysts mimic metastatic lymph nodes during thyroid cancer surgery
por: Jun, Hak Hoon, et al.
Publicado: (2014)

Role of Natural Products in Modulating Histone Deacetylases in Cancer
por: Merarchi, Myriam, et al.
Publicado: (2019)

Papillary thyroid cancer in black thyroid: a case report and literature review
por: Kim, Min Jhi, et al.
Publicado: (2023)

Lateral neck dissection for the treatment of synchronous and metachronous lateral neck metastasis of N1b papillary thyroid cancer
por: Yun, Hyeok Jun, et al.
Publicado: (2023)

New approach of prediction of recurrence in thyroid cancer patients using machine learning
por: Kim, Soo Young, et al.
Publicado: (2021)

PPARγ Targets-Derived Diagnostic and Prognostic Index for Papillary Thyroid Cancer
por: Kim, Jaehyung, et al.
Publicado: (2021)

Aggressiveness of Differentiated Thyroid Carcinoma in Pediatric Patients Younger Than 16 years: A Propensity Score-Matched Analysis
por: Kim, Soo Young, et al.
Publicado: (2022)

Histone Deacetylase Expressions in Hepatocellular Carcinoma and Functional Effects of Histone Deacetylase Inhibitors on Liver Cancer Cells In Vitro
por: Freese, Kim, et al.
Publicado: (2019)

Histone Deacetylases and Histone Deacetylase Inhibitors: Molecular Mechanisms of Action in Various Cancers
por: Sanaei, Masumeh, et al.
Publicado: (2019)

Histone deacetylase 6 in cancer
por: Li, Ting, et al.
Publicado: (2018)

Effects of Anti-Cancer Drug Sensitivity-Related Genetic Differences on Therapeutic Approaches in Refractory Papillary Thyroid Cancer
por: Yun, Hyeok Jun, et al.
Publicado: (2022)

Oleanolic Acid Promotes Neuronal Differentiation and Histone Deacetylase 5 Phosphorylation in Rat Hippocampal Neurons
por: Jo, Hye-Ryeong, et al.
Publicado: (2017)

Dual Targeting of 3-Hydroxy-3-methylglutaryl Coenzyme A Reductase and Histone Deacetylase as a Therapy for Colorectal Cancer()
por: Wei, Tzu-Tang, et al.
Publicado: (2016)

Relationship between Negative Mental Adjustment to Cancer and Distress in Thyroid Cancer Patients
por: Seok, Jeong-Ho, et al.
Publicado: (2013)

Anti-Cancer SERCA Inhibitors Targeting Sorafenib-Resistant Human Papillary Thyroid Carcinoma
por: Chang, Hang-Seok, et al.
Publicado: (2023)

Patient-Derived, Drug-Resistant Colon Cancer Cells Evade Chemotherapeutic Drug Effects via the Induction of Epithelial-Mesenchymal Transition-Mediated Angiogenesis
por: Lim, Jin Hong, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_8l36h0f414mb7dbskeoav69mjh